| (210) | Number of the EPO application | 16763575 |
| (220) | Filing date of the EPO application | 2016.08.03 |
| (80) | EPO patent specification publication (B) | EPB nr. 29/2020, 2020.07.15 |
| (110) | EPO patent number | 3458039 |
| (11) | Number of the document | MD 3458039 T2 |
| (21) | Number of the application | e 2019 0349 |
| (71) | Name(s) of applicant(s), code of the country | Suven Life Sciences Limited, IN; |
| (72) | Name(s) of inventor(s), code of the country | NIROGI Ramakrishna, IN;
SHINDE Anil Karbhari, IN;
JAYARAJAN Pradeep, IN;
BHYRAPUNENI Gopinadh, IN;
KAMBHAMPATI Ramasastri, IN;
JASTI Venkateswarlu, IN; |
| (73) | Name(s) of owner(s), code of the country | SUVEN Life Sciences Limited, IN; |
| (54) | Title of the invention | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | A61K 31/13 (2006.01.01); A61K 31/445 (2006.01.01); A61K 31/496 (2006.01.01); A61P 25/28 (2006.01.01) |
| (19) | Country | IN |
| (41) | Date of publication of the application | 2019.04.30 |
| (49) | Date of publication of the translation of the validated European patent specification | 2020.10.31 |
| (30) | Priority | 201641017204, 2016.05.18, IN |
| (74) | Patent attorney | (Procedură) FOCŞA Valentin, bd. Renaşterii Naţionale, No. 6, of. 08, MD-2024, mun. Chişinău, Republica Moldova |
| (86) | International application | PCT/IB2016/054672, 2016.08.03 |
| (87) | International publication | WO 2017/199070, 2017.11.23 |